Lindsay Fischer

Revumenib treatment results in durable MRD-negative remissions in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia in the phase 2 Augment-101 study.

Alectinib improves disease-free survival in patients with ALK-positive non–small-cell lung cancer.

Axicabtagene ciloleucel produces a higher median overall survival vs high-dose therapy plus autologous stem cell transplant among patients with relapsed or refractory large B-cell lymphoma in the phase 3 ZUMA-7 trial.

Health-related quality of life data support dostarlimab plus chemotherapy as a standard of care in primary advanced or recurrent endometrial cancer, according to an expert from Copenhagen University Hospital in Denmark.

Patients with unresectable hepatocellular carcinoma receiving single tremelimumab regular interval durvalumab have a feasible immune-related adverse effect profile.

The Carolina Frailty Index Score indicates that patients with ovarian cancer classified as frail are highly more likely to die than patients classified as robust.

The lower extremity lymphedema screening questionnaire and gynecological cancer lymphedema questionnaire appear to demonstrate comparable utility in assessing lymphedema in patients with advanced endometrial cancer.

First-line maintenance with avelumab in locally advanced or metastatic urothelial carcinoma yields efficacy that appears consistent between clinical and real-world settings.

Findings from the phase 2 MOUNTAINEER trial indicate that HER2 scoring algorithms may help in identifying which patients are suitable to receive tucatinib plus trastuzumab for metastatic colorectal cancer.

Findings from the phase 3 LEAP-002 study indicate that the addition of pembrolizumab to lenvatinib did not impact quality-of-life scores among patients with hepatocellular carcinoma.

A quadruplet regimen with daratumumab as its base was found to improve health related quality of life in patients with transplant-eligible, newly diagnosed multiple myeloma.

Data from the phase 2 TRIO-US B-12 TALENT trial indicate that fam-trastuzumab deruxtecan-nkxi in the neoadjuvant setting with or without endocrine therapy could be beneficial for patients with hormone receptor–positive, HER2-low breast cancer.

Health-related quality of life data from the phase 2 KEYNOTE-522 trial did not show ill effects of pembrolizumab vs placebo in patients with triple-negative breast cancer.

Findings from the DESTINY-Breast04 trial indicated that patients with hormone receptor–positive, HER2-low metastatic breast cancer experienced promising quality of life following treatment with fam-trastuzumab deruxtecan-nxki.

Phase 1 data on efficacy and safety of ADP-A2M4CD8 in MAGE-A4–positive advanced metastatic disease shows promise at 2022 ESMO.

Dose reductions of ribociclib administered during the phase 2 MONALEESA-2 trial did not have an impact on overall survival for patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Findings from the phase 3 ROMAN trial showed a significant reduction in severe oral mucositis with receipt of avasopasem manganese during chemoradiotherapy for patients with locally advanced, nonmetastatic head and neck cancer.

Findings from a phase 1 study indicate that belimumab could be a safe prophylactic option to prevent chronic graft-versus-host disease in adult patients undergoing allogenic transplant.

Those with inflamed T cell or YAP1–positive extensive-stage small cell lung cancer were likely to gain an improvement in overall survival following treatment with durvalumab and chemotherapy vs those with other overexpressed biomarkers.

To assess the oregovomab combination, a phase 3 trial has launched for patients with advanced epithelial ovarian cancer.

The quality of life was maintained for patients with esophageal cancer plus including gastroesophageal junction adenocarcinoma when treated with pembrolizumab plus chemotherapy.

Risks of skin-related adverse events from nivolumab may be predicted by the presence of Arthrobacter and fatty acid metabolism pathways in the gut microbiome of patients with advanced gastric cancer.

A triplet combination of belantamab mafodotin-blmf plus pomalidomide and dexamethasone yielded a manageable safety profile in a population of patients with relapsed/refractory multiple myeloma.

Patients who have been diagnosed with acute graft-versus-host disease with high levels of amphiregulin could be at a higher risk for early mortality.

Patients with polycythemia vera who have controlled hematocrit and elevated white blood counts can have increased risk of thrombotic events.

In an assessment of 2 patient cases of relapsed or refractory multiple myeloma with translocations in t(11;14), selinexor plus venetoclax was safe and efficacious.

Preclinical data show promise for the novel non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib in mantle cell lymphoma with resistance to both ibrutinib and venetoclax.

Utilizing aromatase inhibitors compared with tamoxifen reduce recurrence in estrogen receptor-positive breast cancer in patients who were menopausal and received ovarian suppression.

One in 3 nurses do not feel emotionally health, a large number of whom have experienced trauma due to the COVID-19 pandemic and no longer wish to be in their job position.

Investigators have identified a gap in end-of-life care among patients with cancer who are dual eligible for Medicare and Medicaid.